Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
TNXP > SEC Filings for TNXP > Form 8-K on 10-Jun-2014All Recent SEC Filings

Show all filings for TONIX PHARMACEUTICALS HOLDING CORP.

Form 8-K for TONIX PHARMACEUTICALS HOLDING CORP.


10-Jun-2014

Submission of Matters to a Vote of Security Holders, Other Ev


Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 9, 2014, Tonix Pharmaceuticals Holding Corp. (the "Company") held its annual meeting of shareholders, at which the Company's shareholders approved four proposals. The proposals are described in detail in the Company's proxy statement filed with the Securities and Exchange Commission on May 2, 2014 pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended.

Proposal 1



The Company's shareholders elected eight individuals to the Board of Directors
as set forth below:



                         Votes      Votes      Broker
        Name              For      Withheld   Non-Votes
Seth Lederman          3,542,628    5,650     3,882,231
Stuart Davidson        3,342,715   205,563    3,882,231
Patrick Grace          3,542,328    5,950     3,882,231
Donald W. Landry       3,544,028    4,250     3,882,231
Ernest Mario           3,344,115   204,163    3,882,231
Charles E. Mather IV   3,543,828    4,450     3,882,231
John Rhodes            3,543,828    4,450     3,882,231
Samuel Saks            3,344,015   204,263    3,882,231

Proposal 2



The Company's shareholders ratified the appointment of EisnerAmper LLP as the
Company's independent registered public accounting firm for the fiscal year
ending December 31, 2014, as set forth below:



  Votes      Votes
   For      Against   Abstentions
7,419,650    2,659       8,200

Proposal 3



The Company's shareholders approved the Tonix Pharmaceuticals Holding Corp. 2014
Stock Incentive Plan, as set forth below:



  Votes      Votes
   For      Against   Abstentions   Broker Non-Votes
3,213,995   318,275     16,008         3,882,231

Proposal 4



The Company's shareholders approved the Tonix Pharmaceuticals Holding Corp. 2014
Employee Stock Purchase Plan, as set forth below:



  Votes      Votes
   For      Against   Abstentions   Broker Non-Votes
3,441,891   90,555      15,832         3,882,231



Item 8.01 Other Events.

On June 10, 2014, the Company issued a press release announcing that the U.S. Food and Drug Administration cleared the Company's investigational new drug ("IND") application to develop TNX-102 SL for the treatment of post-traumatic stress disorder ("PTSD"). The Company further reported that, as a result of the clearance of the IND, the Company will be able to move forward in the third quarter of this year with its planned U.S.-based Phase 2 clinical trial designed to evaluate the safety and efficacy of TNX-102 SL in patients with PTSD.

A copy of the press release that discusses this matter is filed as Exhibit 99.01 to, and incorporated by reference in, this report. The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference in any such filing.



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.01 Press Release, dated June 10, 2014, issued by Tonix Pharmaceuticals Holding Corp.

  Add TNXP to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for TNXP - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.